NOVAVAX INC (NVAX) Form 8-K — Nov 5, 2026
Novavax reported Q3 2026 total revenue of $68 million, down 3% year over year, with product sales of $26 million up 91% and net loss narrowing sharply to $31 million from $202 million a year ago. In October, Sanofi's launch of a Phase 3 influenza-COVID-19 combination vaccine trial in Europe triggered a $125 million milestone payment to Novavax, and Sanofi confirmed plans for a U.S. Phase 3 trial in 2027; Novavax is eligible for an additional $225 million milestone on U.S. CIC launch plus high single-digit to sub-teen royalties.
Key figures
- Revenue
- 68298000
- Guidance
- Full-year 2026 Adjusted Total Revenue raised to $385-$415M (midpoint $400M, +$145M vs prior); GAAP Combined R&D and SG&A expenses improved to $375-$395M; Non-GAAP Combined R&D and SG&A $315-$335M
- Total Debt
- 292088000
- Revenue Yoy
- -3%
- Total Assets
- 888005000
- Cash Position
- 627000000
- Cash dec 31 2025
- $751 million
- Product sales q3
- 26
- Prior year net loss
- $202 million Q3 2025
- Stockholders deficit
- -$216.9 million
- Sanofi milestone earned
- $125 million (October 2026, Phase 3 CIC trial initiation in Europe)
- Future sanofi milestones
- ["$75 million technology transfer (mid-2027)","$225 million U.S. CIC commercial launch"]
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.